Safety profile of esomeprazole: Results of a prescription-event monitoring study of 11 595 patients in England

Drug Safety

Volumn 31, Issue 4, 2008, Pages 313-323

  Davies, Miranda ^a   Wilton, Lynda V ^a,b   Shakir, Saad A W ^a,b  

^a DRUG SAFETY RESEARCH UNIT   (United Kingdom)

^b UNIVERSITY OF PORTSMOUTH   (United Kingdom)

Author keywords

Adverse drug reactions incidence; Esomeprazole, adverse reactions; Prescription event monitoring; Various toxicities, drug induced

Indexed keywords

ESOMEPRAZOLE; OMEPRAZOLE;

ABDOMINAL PAIN; ABNORMAL SENSATION; ADULT; AGED; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ARTHRALGIA; ARTICLE; BURNING SENSATION; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CONJUNCTIVITIS; COUGHING; DEATH; DIARRHEA; DIPLOPIA; DIZZINESS; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MONITORING; DRUG SAFETY; DYSPEPSIA; DYSPNEA; EAR DISEASE; EDEMA; ENDOCRINE DISEASE; ERYTHEMA; ERYTHEMA NODOSUM; ERYTHROCYTE; EYE DISEASE; FACE EDEMA; FEMALE; GASTROINTESTINAL DISEASE; GENERAL PRACTITIONER; HAIR LOSS; HALLUCINATION; HEADACHE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART PALPITATION; HEMATOMA; HUMAN; HYPONATREMIA; IMMUNOPATHOLOGY; JAUNDICE; LACRIMATION DISORDER; LASSITUDE; LEUKOPENIA; LIMB PAIN; LIMB SWELLING; LIVER FUNCTION TEST; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALAISE; MALE; MENTAL DISEASE; METABOLIC DISORDER; MIGRAINE; MUSCLE RIGIDITY; MUSCLE WEAKNESS; MUSCULOSKELETAL DISEASE; MUSCULOSKELETAL STIFFNESS; MYALGIA; NAUSEA; PARESTHESIA; PERIPHERAL NEUROPATHY; PHARYNGITIS; PHOTOSENSITIVITY; POSTMARKETING SURVEILLANCE; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PRURITUS; QUESTIONNAIRE; RASH; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SKIN DISEASE; TONGUE SWELLING; UNITED KINGDOM; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; VASCULITIS; VERTIGO; VISUAL DISORDER; VOMITING; XEROSTOMIA;

ADVERSE DRUG REACTION REPORTING SYSTEMS; COHORT STUDIES; DIARRHEA; DRUG MONITORING; DYSPEPSIA; ENGLAND; ESOPHAGEAL DISEASES; FEMALE; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PRIMARY HEALTH CARE; PRODUCT SURVEILLANCE, POSTMARKETING; PROTON PUMP INHIBITORS;

EID: 41149123885     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200831040-00005     Document Type: Article

References (28)

1. Rawlins MD, Jefferys DB. United Kingdom product licence applications involving new active substances, 1987-1989: their fate after appeals. Br J Clin Pharmacol 1993 Jun; 35 (6): 599-602
2. Waller PC, Coulson RA, Wood SM. Regulatory pharmacovigilance in the United Kingdom: current principles and practice. Pharmacoepidemiol Drug Saf 1996 Nov; 5 (6): 363-75
3. Thitiphuree S, Talley NJ. Esomeprazole, a new proton pump inhibitor: pharmacological characteristics and clinical efficacy. Int J Clin Pract 2000; 54 (8): 537-41
4. Scott LJ, Dunn CJ, Mallarkey G, et al. Esomeprazole: a review of its use in the management of acid-related disorders. Drugs 2002; 62 (10): 1503-38
5. Shakir SA. PEM in the UK. In: Mann RD, Andrews E, editors. Pharmacovigilance. 1st ed. Chichester: John Wiley & Sons Ltd, 2002: 333-44
6. Shakir SAW. Causality and correlation in pharmacovigilance. In: Talbot J, Waller PC, editors. Stephens' detection of new adverse drug reactions. 5th ed. Chichester: John Wiley & Sons Ltd, 2004: 329-43
7. Strom B. Sample size considerations for pharmaco-epidemiology studies. In: Strom B, editor. Pharmaco-epidemiology. 2nd ed. Chichester: John Wiley & Sons Ltd, 1994: 31-9
8. Machin D, Campbell M, Fayers P, et al. Post marketing surveillance: sample sizes required to observe a single adverse reaction with a given probability and anticipated incidence. In: Machin D, editor. Sample size tables for clinical studies. 2nd ed. Oxford: Blackwell Science Ltd, 1997: 150
9. Machin D, Campbell M, Fayers P, et al. Post marketing surveillance: sample sizes for detection of a specified adverse reaction, background incidence known. In: Machin D, editor. Sample size tables for clinical studies. 2nd ed. Oxford: Blackwell Science Ltd, 1997: 151-3
10. CIOMS/WHO. International guidelines for biomedical research involving human subjects. Geneva: CIOMS/WHO, 2002
11. Royal College of Physicians. Guidelines on the practice of ethical committees in medical research involving human subjects. 3rd ed. London: Royal College of Physicians of London, 1996
12. Department of Health. Supplementary operational guidelines for NHS Research Ethics Committees - November 2000: multi-centre research in the NHS the process of ethical review when there is no local researcher [online]. Available at URL: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/ PublicationsPolicyAndGuidance/DH_4006696 [Accessed 2008 Mar 14]
13. Castell DO, Kahrilas PJ, Richter JE, et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002; 97 (3): 575-83
14. Maton PN, Vakil NB, Levine JG, et al. Safety and efficacy of long term esomeprazole therapy in patients with healed erosive oesophagitis. Drug Saf 2001; 24 (8): 625-35
15. Shakir SAW. Prescription-event monitoring. In: Strom B, editor. Pharmacoepidemiology. 4th ed. Chichester: John Wiley & Sons Ltd; 2005: 203-16
16. Martin RM, Dunn NR, Freemantle S, et al. The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: cohort studies. Br J Clin Pharmacol 2000 Oct; 50 (4): 366-72
17. Wilton LV, Key C, Shakir SA. The pharmacovigilance of pantoprazole: the results of postmarketing surveillance on 11541 patients in England. Drug Saf 2003; 26 (2): 121-32
18. AstraZeneca. Nexium (Esomeprazole) [summary of product characteristics]. 2000 Jul
19. AstraZeneca. Nexium (Esomeprazole) [summary of product characteristics]. 2003 Jan
20. Schöuhöfer PS, Werner B, Troger U. Ocular damage associated with proton pump inhibitors. BMJ 1997 Jun 21; 314 (7097): 1805
21. Riordan-Eva P, Sanders MD. Omepraxole and ocular damage: facts of cases are unclear. BMJ 1998 Jan 3; 316 (7124): 67
22. Lessell S. Omepraxole and ocular damage: concerns on safety of drug are unwarranted. BMJ 1998 Jan 3; 316 (7124): 67
23. Garcia Rodriguez LA, Mannino S, Wallander MA, et al. A cohort study of the ocular safety of anti-ulcer drugs. Br J Clin Pharmacol 1996 Aug; 42 (2): 213-6
24. Lalkin A, Loebstein R, Addis A, et al. The safety of omeprazole during pregnancy: a multicenter prospective controlled study. Am J Obstet Gynecol 1998 Sep; 179 (3 Pt 1): 727-30
25. Kallen BA. Use of omeprazole during pregnancy: no hazard demonstrated in 955 infants exposed during pregnancy. Eur J Obstet Gynecol Reprod Biol 2001 May; 96 (1): 63-8
26. Nikfar S, Abdollahi M, Moretti ME, et al. Use of proton pump inhibitors during pregnancy and rates of major malformations: a meta-analysis. Dig Dis Sci 2002 Jul; 47 (7): 1526-9
27. Ruigomez A, Garcia Rodriguez LA, Cattaruzzi C, et al. Use of cimetidine, omeprazole, and ranitidine in pregnant women and pregnancy outcomes. Am J Epidemiol 1999 Sep 1; 150 (5): 476-81
28. Bateman DN, Colin-Jones D, Hartz S, et al. Mortality study of 18 000 patients treated with omeprazole. Gut 2003 Jul; 52 (7): 942-6